Adaptive Biotechnologies stock hits 52-week high at $13.73

Adaptive Biotechnologies Corp stock reached a significant milestone, hitting a 52-week high at $13.73, with a market capitalization of $2.08 billion. According to InvestingPro data, the company maintains a healthy current ratio of 2.84, indicating strong liquidity position. This achievement reflects a remarkable 1-year change of 184.73%, showcasing the company’s strong performance in the market over the past year. The rise in stock value underscores investor confidence and interest in Adaptive Biotechnologies’ potential for growth and innovation in the biotechnology sector, supported by impressive revenue growth of 21.6%. As the company continues to advance its research and development efforts, market participants are closely watching its trajectory and the broader impact of its technological advancements. InvestingPro analysis suggests the stock is trading above its Fair Value, with 11 additional exclusive insights available for subscribers.

In other recent news, Adeptus Biotechnologies announced the termination of its collaboration and license agreement with Genentech, effective February 9, 2026. This decision will release Adeptus from exclusivity obligations related to cell therapies in oncology, allowing the company to explore other licensing opportunities. In light of this development, BTIG reiterated its Buy rating on Adeptus and maintained a price target of $14.00. Piper Sandler also raised its price target for Adeptus to $15.00, citing a significant growth outlook driven by volume acceleration in its MRD business and anticipated gains from EMR integrations. Additionally, Morgan Stanley increased its price target to $11.00, acknowledging continued momentum in clonoSEQ volume and average selling price. BTIG further raised its price target from $13.00 to $14.00, following Adeptus’s robust second-quarter performance. The company exceeded earnings expectations and achieved adjusted EBITDA positivity in its core MRD business earlier than planned. These developments reflect a positive outlook from analysts on Adeptus Biotechnologies’ future performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.